Acute Myeloid Leukemia Real World Treatment Patterns

Pfizer

Overview

Among patients with a diagnosis of AML who received non-intensive chemotherapy: * Describe patient demographic and clinical characteristics * Describe treatment patterns * Describe effectiveness outcomes * Evaluate tumor response

Study Type

OBSERVATIONAL

Conditions

Leukemia, Myeloid, Acute

Interventions

azacitidineDRUG

Patients taking azacitidine

venetoclaxDRUG

patients taking venetoclax

glasdegibDRUG

patients taking glasdegib

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study: 1. Confirmed diagnosis of AML on or after 01 January 2012 through Clinical Research Nurse (CRN) review of provider documentation of AML diagnosis in the medical record. 2. Receipt of non-intensive therapy at any point during first line therapy following initial AML diagnosis. For this study, non-intensive therapy will be defined as 1 of the following agents, alone or in combination with any other agent: 1. AZA 2. GLAS 3. VEN 3. Age ≥18 years at initial diagnosis of AML. Exclusion Criteria: Patients meeting any of the following criteria will not be included in the study: 1\. Record of 1 or more of the following confounding diagnoses at any point before or after AML diagnosis: Acute lymphoblastic leukemia; acute promyelocytic leukemia, aggressive systemic mastocytosis; hypereosinophilic syndrome and/or chronic eosinophilic leukemia; dermatofibrosarcoma protuberans; gastrointestinal stromal tumors.